Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CD123 CAR-T in AML
NCT03796390Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Dec 2018
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute myeloid leukemia (AML), sponsored by Senlang Bio. Primary endpoints: Tumor load up to 12 months and Adverse Events and Cytokine Storm Response up to 12 months. Status: unknown.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03796390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796390.